CLINICAL CHARACTERISTICS OF PATIENTS WITH DIABETIC FOOT ULCERS AND PATHOGENS ISOLATED FROM WOUND CULTURES

  • Gulsah Elbuken Namık Kemal University Faculty of Medicine, Department of Endocrinology and Metabolism, Tekirdag, Turkey
  • Gulsah Elbuken Namık Kemal University Faculty of Medicine, Department of Endocrinology and Metabolism, Tekirdag, Turkey
  • Birol Safak Namık Kemal University Faculty of Medicine, Department of Microbiology, Tekirdag, Turkey
  • Mahizar Mammadova Namık Kemal University Faculty of Medicine, Department of Internal Medicine, Tekirdag, Turkey
  • Ismail Yildiz Namık Kemal University Faculty of Medicine, Department of Endocrinology and Metabolism, Tekirdag, Turkey
  • Ugur Tosun Namık Kemal University Faculty of Medicine, Department of Department of Aesthetic, Plastic and Reconstructive Surgery, Tekirdag, Turkey
  • Sayid Shafi Zuhur Namık Kemal University Faculty of Medicine, Department of Endocrinology and Metabolism, Tekirdag, Turkey
Keywords: Diabetic foot ulcer, diabetic foot infection, diabetic foot, microorganisms, wound culture

Abstract

Objective: Diabetic foot ulcers (DFUs) are a major cause of morbidity and mortality and develop in the presence of peripheral vascular ischemia and neuropathy. Poorly controlled diabetes is an additional risk factor. DFUs are often polymicrobial. The types of isolated microorganisms (MOs) show regional variations: Gram-negative MOs are more common in temperate climate regions such as Africa and Asia and Gram-positive pathogens are more prevalent in western regions. We conducted a retrospective review of microorganisms isolated from 24 patients with DFUs.

Methodology: Twenty-four patients (17 males, 7 females) with a mean (±SD) age of 64.5±8.7 years were included. There was no significant difference in age between males and females. All patients had type 2 Diabetes Mellitus (DM) with a mean disease duration of 15±7 years.

Results: Considering the type of ulceration, 5 patients had superficial infections such as cellulitis, 16 patients had ulcers with the involvement of subcutaneous tissues and 3 patients had gangrenous ulcers. The diameter of ulcer was less than 2 cm in 9 patients, 2 to 4 cm in 11 patients and greater than 4 cm in 4 patients. The growth of the following MOs as single agents were detected in the wound cultures: Staphylococcus aureus in 5 patients, Escherichi acoli in 4, Morganella morganii in 4, Pseudomonas aeruginosa in 3, Klebsiella pneumoniae in 1, Serratia marcescens in 1, Proteus mirabilis in 1, Enterococcus faecalis in 1, and Stenotrophomonas maltophilia in 1 patient. Three patients showed concomitant growth of 2 pathogens (Enterobacter aerogenes+Escherichia coli; Enterobacter aerogenes+Staphylococcus aureus; Pseudomonas aeruginosa+Staphylococcus aureus). Peripheral artery disease (PAD) was present in 10 patients. Six microorganismsElbuken G. et al., Med. Res. Chronicles., 6(2), 68-76 2019 The corresponding author* patients were being treated with antibiotics (ABs) and local wound care including regular dressing changes and 18 patients required surgical treatment (debridement and local flap in 14 and amputation in 4). Of 4 amputated patients, 2 had a history of toe amputation. The average length of hospitalization was 12.9 ±7.1 days, mean HbA1c level was 8.1±1.6%, and mean duration of AB treatment was 11.7±3.2 days.

Discussion and Conclusion: Despite earlier diagnosis of DM and current availability of more effective therapeutic options, DFUs are still the leading cause of amputation. Along with blood glucose regulation, careful follow-up of diabetic complications and timely implementation of preventive actions would substantially reduce hospitalization and loss of productivity.

Downloads

Download data is not yet available.

References

1. Boulton AJ, Armstrong DG, Albert SF, et al. Comprehensive foot examination and risk assessment: a report of the task force of the foot care interest group of theElbuken G. et al., Med. Res. Chronicles., 6(2), 68-76 2019 American Diabetes Association, with endorsement by the American Association of Clinical Endocrinologists. Diabetes Care 31, 2008, 1679.
2. Pecoraro RE, Reiber GE, Burgess EM. Pathways to diabetic limb amputation. The basis for prevention. Diabetes Care 13, 1990, 513.
3. Singh N, Armstrong DG, Lipsky BA. Preventing foot ulcers in patients with diabetes. JAMA 293, 2005, 217.
4. Cheer K, Shearman C, Jude EB. Managing complications of the diabetic foot. BMJ 339, 2009, b4905.
5. Lipsky BA, Berendt AR, Deery HG, Embil JM, Joseph WS, Karchmer AW, et al. Infectious Diseases Society of America guidelines. Diagnosis and treatment of diabetic foot infections. Clin Infect Dis. 39(7), 2004, 885–910.
6. Lipsky BA, Berendt AR, Cornia PB, Pile JC, Peters EJ, Armstrong DG, Deery HG, Embil JM, Joseph WS, Karchmer AW, Pinzur MS, Senneville E; Infectious Diseases Society of America. 2012 Infectious Diseases Society of America clinical practice guideline for the diagnosis and treatment of diabetic foot infections. Clin Infect Dis. 54(12), 2012, e132-73.
7. Hatipoglu M, Mutluoglu M, Uzun G, et al. The microbiologic profile of diabetic foot infections in Turkey: a 20-year systematic review: diabetic foot infections in Turkey. Eur J Clin Microbiol Infect Dis. 33, 2014, 871.
8. Ramakant P, Verma AK, Misra R, et al. Changing microbiological profile of pathogenic bacteria in diabetic foot infections: time for a rethink on which empirical therapy to choose? Diabetologia 54, 2011, 58.
9. Zubair M, Malik A, Ahmad J. Clinicomicrobiological study and antimicrobial drug resistance profile of diabetic foot infections in North India. Foot (Edinb) 21, 2011, 6.
10. Leclercq R, Canton R, Brown DF, Giske CG., Heisig P, MacGowan AP, et al. EUCAST expert rules in antimicrobial susceptibility testing. Clin Microbiol Infect, 19, 2013, 141-160.
11. Demir T, Akıncı B, Yeşil S. Diyabetik ayak ülserlerinin tanı ve tedavisi. DEÜ Tıp Fak. Derg. 1, 2007, 63-70.
12. Torreguitart MV. Diabetic foot care. Importance of education. Rev Ferm. 34(5), 2011, 25-30.
13. Wu SC, Driver VR, Wrobel JS, Armstrong DG. Foot ulcers in the diabetic patient, prevention and treatment. Vasc Health Risk Manag. 3(1), 2007, 65-76.
14. Vardakas KZ, Horianopoulou M, Falagas ME. Factors associated with treatment failure in patients with diabetic foot infections: an analysis of data from randomized controlled trials. Diabetes Res Clin Pract. 80(3), 2008, 344-351.
15. Wagner WF. The dysvascular foot: a system for diagnosis and treatment. Foot Ankle, 2, 1981, 64-67.
16. Lipsky BA, Aragon-Sanchez J, Diggle M, Embil J, Kono S, Lavery L, Senneville E, Urbančič-Rovan V, Van Asten S;International Working Group on the Diabetic Foot, Peters EJ. IWGDF guidance on the diagnosis and management of foot infections in persons with diabetes. Diabetes Metab Res Rev. 32 (1),2016, 45-74.
17. Seth A, Attri AK, Kataria H, Kochhar S, Seth SA, Gautam N. Clinical Profile and Outcome in Patients of Diabetic Foot Infection. Int J Appl Basic Med Res. 9(1), 2019, 14-19.
18. Tardáguila-García A, Lázaro-Martínez JL, Sanz-Corbalán I, García-Álvarez Y, Álvaro-Afonso FJ, García-Morales E.Correlation between Empirical Antibiotic Therapy and Bone Culture Results in Patients with Osteomyelitis. Adv Skin Wound Care 32(1), 2019, 41- 44.
19. Kwon KT, Armstrong DG. Microbiology and Antimicrobial Therapy for Diabetic Foot Infections.Infect Chemother. 50(1), 2018, 11-20.
20. Saltoglu N, Ergonul O, Tulek N, Yemisen M, Kadanali A, Karagoz G, et al. Turkish Society of Clinical Microbiology andElbuken G. et al., Med. Res. Chronicles., 6(2), 68-76 2019 Infectious Diseases, Diabetic Foot Infections Study Group. Influence of multidrug resistant organisms on the outcome of a diabetic foot infection.Int J
Infect Dis. 70, 2018, 10-14.
21. Cunha BA. Antibiotic selection for diabetic foot infections: a review. J Foot Ankle Surg. 39, 2000, 253-257.
22. Guillameta CV, Kollef MA. How to stratify patients at risk for resistant bugs in the skin and soft tissue infections?.Curr Opin Infect Dis. 29, 2016, 116–123.
23. Gariani K, Lebowitz D, Kressmann B, von Dach E, Sendi P, Waibel F, Berli M, Huber T, Lipsky BA, UçkayI.Oral Amoxicillin/ Clavulanate for Treating Diabetic Foot Infections. Diabetes Obes Metab., 2019 [Epub ahead of print].
How to Cite
1.
Gulsah Elbuken, Gulsah Elbuken, Birol Safak, Mahizar Mammadova, Ismail Yildiz, Ugur Tosun, Sayid Shafi Zuhur. CLINICAL CHARACTERISTICS OF PATIENTS WITH DIABETIC FOOT ULCERS AND PATHOGENS ISOLATED FROM WOUND CULTURES. Med. res. chronicles [Internet]. 2019Apr.30 [cited 2024Apr.19];6(2):68-6. Available from: https://medrech.com/index.php/medrech/article/view/371
Section
Original Research Article